Gaucher Disease, Type 1 — Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)
Citation(s)
Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Adult Patients With Type 1 Gaucher Disease, Previously on a Stable Dose of VPRIV for at Least 3 Months: an Extension of the Investigator-initiated Study